<![CDATA[Carotuximab/Radium-223 Will Be Evaluated in Bone-Involved Metastatic CRPC]]>

Trial Startcarotuximabradium-223Positive

AI Analysis

Summary

Investigators will evaluate a combination of carotuximab and radium-223 in patients with bone-involved metastatic castration-resistant prostate cancer to address treatment resistance.

Clinical Trial Data

Importance:4/10

Sentiment:

0.30

oncologyprostate cancerCRPCbone metastasescombination therapyclinical trial

Read the original article

Published by Cancer Network on July 22, 2026 3:30 PM

Read Original